ALKS Alkermes plc.

8-K Current Report

Filed: February 25, 2026

Health Care

Pharmaceutical Preparations

Alkermes plc. (ALKS) 8-K current report filed with SEC EDGAR on February 25, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
2 items

Item 5.02: Departure/Election of Directors or Officers
Item 7.01: Regulation FD Disclosure

AI Filing Analysis
8-K

Item 5.02 · Departure/Election of Directors or Officers

• CEO Richard F. Pops retiring July 31, 2026 after 35 years, transitioning to Senior Advisor through December 31, 2026 and non-executive Chairman role
• Blair C. Jackson, EVP and COO since 2021, appointed CEO effective August 1, 2026, bringing operational leadership and prior strategic roles

+3 more insights

Item 7.01 · Regulation FD Disclosure

• CEO transition announced: Mr. Pops retiring, Mr. Jackson named successor effective immediately
• Leadership change could signal new strategic direction or operational priorities

+2 more insights

Other Alkermes plc. 8-K Filings

8-K Feb 25, 2026

Get deeper insights on Alkermes plc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.